Dana V. Rizk - Concepedia

Author

Dana V. Rizk

University of Alabama at Birmingham ORCID

Also Known As

D Rizk, D. Rizk, D. Rizk V, D. V. Rizk, D., Rizk, D.V. Rizk, Dana Rizk, Dana V Rizk, Dana V. Rizk, Dana V. Rizk

173

Publications

4.4K

Citations

H-Index

Concepts

All Affiliations

University of Alabama at Birmingham Emory University University of Michigan University of Leicester Hospital Británico de Buenos Aires

About

Dana V. Rizk is an author at University of Alabama at Birmingham specializing in nephrology, medicine, and chronic kidney disease.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	11	12	902
2	Public Health	2	2	205
3	Health Sciences	1	1	21
4	Language Studies	1	1	15
5	Counseling	1	1	50

Dana V. Rizk

Publications

2.9K

Citations

H-Index

Page 1

	Year	Citations
Rituximab or Cyclosporine in the Treatment of Membranous Nephropathy Fernando C. Fervenza, Gerald B. Appel, Sean J. Barbour, New England Journal of Medicine	2019	554
Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial Brad H. Rovin, Jonathan Barratt, Hiddo J.L. Heerspink, The Lancet	2023	224
Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy Jonathan Barratt, Richard Lafayette, Jens Kristensen, Kidney International	2022	205
Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial Hiddo J.L. Heerspink, Jai Radhakrishnan, Charles E. Alpers, The Lancet GlomerulonephritisActive-controlled Clinical TrialRenal FunctionKidney FailureChronic Kidney Disease	2023	203
Dietary Patterns and Risk of Death and Progression to ESRD in Individuals With CKD: A Cohort Study Orlando M. Gutiérrez, Paul Muntner, Dana V. Rizk, American Journal of Kidney Diseases NutritionDietary PatternsUrologyNutritional EpidemiologyMedicine	2014	155
CureGN Study Rationale, Design, and Methods: Establishing a Large Prospective Observational Study of Glomerular Disease Laura Mariani, Andrew S. Bomback, Pietro A. Canetta, American Journal of Kidney Diseases Glomerular DiseaseGlomerulonephritisHemodialysisRenal FunctionRenal Disease	2018	131
Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy Vlado Perkovic, Jonathan Barratt, Brad H. Rovin, New England Journal of Medicine	2024	117
Results of a randomized double-blind placebo-controlled Phase 2 study propose iptacopan as an alternative complement pathway inhibitor for IgA nephropathy Hong Zhang, Dana V. Rizk, Vlado Perkovic, Kidney International	2023	109
Glomerular Immunodeposits of Patients with IgA Nephropathy Are Enriched for IgG Autoantibodies Specific for Galactose-Deficient IgA1 Dana V. Rizk, Manish K. Saha, Stacy Hall, Journal of the American Society of Nephrology	2019	108
Cardiovascular Risk Factors in CKD Associate with Both ESRD and Mortality Paul Muntner, Suzanne E. Judd, Liyan Gao, Journal of the American Society of Nephrology	2013	104

Page 1